

## EDITORIAL COMMENT

# Asian Ethnicity Is Not a Risk Factor for Heart and Lung Transplantation\*



Seonhwa Lee, MD, In-Cheol Kim, MD, PhD

Among the various types of solid organ transplantation, lung transplantation, followed by heart transplantation, shows the worst outcomes.<sup>1</sup> Besides the severity of the underlying disease status of recipients, several factors affect post-transplantation survival, such as limited availability of living donors and high incidence of coexisting infections.<sup>2</sup> In heart and lung transplantation (HLT<sub>x</sub>), combined risk factors associated with both heart and lung diseases lead to challenges of perioperative and long-term patient management, which can further decrease post-transplantation survival.<sup>3</sup>



The International Society for Heart & Lung Transplantation reports a continuously decreasing number of HLT<sub>x</sub> procedures. There were more than 200 cases in the 1990s and <100 cases after 2005, with only 59 procedures performed in 2017.<sup>4</sup> Worse survival after combined HLT<sub>x</sub> compared with single heart or lung transplantation and difficulties in appropriate recipient and donor selection because of the shortage of donors might be the reasons for the declining trend of cases. In Asian countries, a traditionally conservative cultural background regarding organ donation has hindered widespread transplantation, especially multiorgan transplantations.<sup>5</sup> Between 2010 and

2018, 21 HLT<sub>x</sub> cases were performed in Korea, and only 2 cases were reported in Japan (Figure 1).<sup>6</sup> According to United Network for Organ Sharing data, the Asian population accounts for an extremely low proportion of HLT<sub>x</sub>.<sup>7</sup>

The long-held myth that Asian patients with smaller body sizes are more vulnerable during critical management has also affected the underuse of HLT<sub>x</sub> in Asian compared with Western populations. In this issue of *JACC: Asia*, research by Shudo et al<sup>7</sup> gives us important insight that outcomes after HLT<sub>x</sub> are similar to those among non-Hispanic White patients. Better compliance with optimal management strategies including self-care, immunosuppressive regimens, and surveillance protocols could affect equal or even better outcomes in Asian patients. For the successful treatment of life-threatening end-stage heart and lung disorders, 3 important determinants need to be considered: 1) appropriate recipient and donor selection; 2) optimal pretransplantation recipient care; and 3) maintaining the best level of post-transplantation management with a multidisciplinary team approach during treatment (Figure 2). Careful selection for HLT<sub>x</sub> candidates with end-stage heart and lung disorders but without evidence of irreversible other organ dysfunction is of the utmost importance. During management with inotropic agents, mechanical ventilation, or extracorporeal membrane oxygenation, optimal recipient management and adequate control of comorbidities, including infection, are crucial. When an available donor is matched, meticulous and multidimensional evaluation can lead to a better post-transplantation outcome. Finally, post-transplantation treatment with all the related departments could maximize patient survival. It should be emphasized that there is no perfect road to successful HLT<sub>x</sub>, and improvement of the survival rate can be the main driving force for

\*Editorials published in *JACC: Asia* reflect the views of the authors and do not necessarily represent the views of *JACC: Asia* or the American College of Cardiology.

From the Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Keimyung University School of Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).



the expansion of HLTx worldwide, including Asian countries.

#### FUNDING SUPPORT AND AUTHOR DISCLOSURES

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

---

**ADDRESS FOR CORRESPONDENCE:** Dr In-Cheol Kim, Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Keimyung University Dongsan Hospital, Keimyung University College of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu 42601, Republic of Korea. E-mail: [kimic@dsmc.or.kr](mailto:kimic@dsmc.or.kr).

#### REFERENCES

1. Graham CN, Watson C, Barlev A, Stevenson M, Dharnidharka VR. Mean lifetime survival estimates following solid organ transplantation in the US and UK. *J Med Econ.* 2022;25:230-237.
2. Date H. Current status and problems of lung transplantation in Japan. *J Thorac Dis.* 2016;8: S631-S636.
3. Dimopoulos K, Muthiah K, Alonso-Gonzalez R, et al. Heart or heart-lung transplantation for patients with congenital heart disease in England. *Heart.* 2019;105:596-602.
4. Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report—2019; focus theme: donor and recipient size match. *J Heart Lung Transplant.* 2019;38:1042-1055.
5. Kim IC, Youn JC, Kobashigawa JA. The past, present and future of heart transplantation. *Korean Circ J.* 2018;48:565-590.
6. Okada Y, Chida M, Nakajima J, et al. Current status of lung transplantation in Japan—report from Japanese lung transplant registry. *J Vis Surg.* 2021;7:13.
7. Shudo Y, Leipzig M, He H, et al. Combined heart-lung transplantation outcomes in Asian populations: national database analysis. *JACC: Asia.* 2022;2:504-512.

---

**KEY WORDS** Asia, ethnicity, heart lung transplantation, multidisciplinary